Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Akshat Jain: NEJM Group Study Demonstrates Platelet Responses in ITP Treated with Mezagitamab
Akshat Jain/Photo: lluh.org
Apr 26, 2026, 13:47

Akshat Jain: NEJM Group Study Demonstrates Platelet Responses in ITP Treated with Mezagitamab

Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared a post on LinkedIn about a recent article by David J. Kuter et al. published in NEJM, adding:

“Exciting new data in ITP treatment : a phase 2 NEJM Group study found that mezagitamab, a CD38-targeting antibody, produced rapid and sustained platelet responses, with the highest dose showing a platelet response in 91% of patients by week 16 and a safety profile similar to placebo.

Why this matters: ITP remains an area of major unmet need, and this therapy may represent a true shift from symptom control toward disease modification by targeting the immune cells driving platelet destruction.

If confirmed in phase 3, mezagitamab could meaningfully change the treatment landscape for patients who do not respond well to current options.

600 mg dose achieving a platelet response in 91% of patients by week 16 and a tolerability profile comparable to placebo.

This is especially important in ITP, where many patients still have limited durable responses to existing therapies.

By targeting CD38-expressing immune cells, mezagitamab may offer a more disease-modifying approach rather than just temporary platelet support.”

Title: A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia

Authors: David J. Kuter, Katsuhiro Miura, Andrea Patriarca, Dražen Pulanić, Atanas Radinoff, Katya Sapunarova, Antonia Syrigou, Renchi Yang, Van Anh Nguyen, Emily Skelton, Scarlett Wang, Donald L. Yee, Parth Patwari

Akshat Jain: NEJM Group Study Demonstrates Platelet Responses in ITP Treated with Mezagitamab

Stay updated on all scientific advances with Hemostasis Today.

 

 

Akshat Jain Andrea Patriarca Antonia Syrigou Atanas Radinoff David J. Kuter Donald L. Yee Dražen Pulanić Emily Skelton Health Hematology Hemostasis Hemostasis News Hemostasis Today Katsuhiro Miura Katya Sapunarova Medicine NEJM Parth Patwari Renchi Yang Scarlett Wang Van Anh Nguyen
NewsFeed